Advertisement

Autoantibodies pp 243-253 | Cite as

Use of a Citrullinated Peptide Panel for Detection of Anti-Citrullinated Protein Antibodies by Enzyme-Linked Immunosorbent Assay

  • Nicole Hartwig TrierEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1901)

Abstract

Anti-citrullinated protein antibodies (ACPA)s are a hallmark of rheumatoid arthritis (RA) and are essential for serological diagnosis of RA.

ACPAs are not specific for a single citrullinated target; in fact, several citrullinated ACPA target proteins have been described. As a consequence, ACPAs are primarily detected by enzyme-linked immunosorbent assays, where several citrullinated peptides are used as target antigens.

This chapter focuses on the detection of ACPAs using a recently developed peptide panel in enzyme-linked immunosorbent assays.

Key words

Citrullinated epitopes Immunoassay Streptavidin capture ELISA Peptides Rheumatoid arthritis 

References

  1. 1.
    Alamanos Y, Drosos AA (2005) Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 4:130–136CrossRefGoogle Scholar
  2. 2.
    Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094–1108CrossRefGoogle Scholar
  3. 3.
    Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, Simon M, Senshu T, Masson-Bessiere C, Jolivet-Reynaud C, Jolivet M, Serre G (1999) The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 162:585–594PubMedGoogle Scholar
  4. 4.
    Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273–281CrossRefGoogle Scholar
  5. 5.
    Tarcsa E, Marekov LN, Mei G, Melino G, Lee SC, Steinert PM (1996) Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem 271:30709–30716CrossRefGoogle Scholar
  6. 6.
    Snir O, Widhe M, Hermansson M, von Spee C, Lindberg J, Hensen S, Lundberg K, Engstrom A, Venables PJ, Toes RE, Holmdahl R, Klareskog L, Malmstrom V (2010) Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 62:44–52CrossRefGoogle Scholar
  7. 7.
    Burkhardt H, Sehnert B, Bockermann R, Engstrom A, Kalden JR, Holmdahl R (2005) Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 35:1643–1652CrossRefGoogle Scholar
  8. 8.
    Dam CE, Houen G, Trier NH (2016) The dependency on neighboring amino acids for reactivity of anti-citrullinated protein antibodies to citrullinated proteins. Scand J Clin Lab Invest 76:417–425CrossRefGoogle Scholar
  9. 9.
    Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, Moyes D, Taylor PC, Venables PJ (2005) Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 7:R1421–R1429CrossRefGoogle Scholar
  10. 10.
    Sebbag M, Moinard N, Auger I, Clavel C, Arnaud J, Nogueira L, Roudier J, Serre G (2006) Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol 36:2250–2263CrossRefGoogle Scholar
  11. 11.
    Trier NH, Holm BE, Slot O, Locht H, Lindegaard H, Svendsen A, Nielsen CT, Jacobsen S, Theander E, Houen G (2016) Application of synthetic peptides for detection of anti-citrullinated peptide antibodies. Peptides 76:87–95CrossRefGoogle Scholar
  12. 12.
    Uysal H, Nandakumar KS, Kessel C, Haag S, Carlsen S, Burkhardt H, Holmdahl R (2010) Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunol Rev 233:9–33CrossRefGoogle Scholar
  13. 13.
    Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, van Venrooij WJ, Menard HA (2004) Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 6:R142–R150CrossRefGoogle Scholar
  14. 14.
    Ioan-Facsinay A, el-Bannoudi H, Scherer HU, van der Woude D, Menard HA, Lora M, Trouw LA, Huizinga TW, Toes RE (2011) Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 70:188–193CrossRefGoogle Scholar
  15. 15.
    Trier NH, Dam CE, Olsen DT, Hansen PR, Houen G (2015) Contribution of peptide backbone to anti-citrullinated peptide antibody reactivity. PLoS One 10:e0144707CrossRefGoogle Scholar
  16. 16.
    Trier NH, Hansen PR, Vedeler CA, Somnier FE, Houen G (2012) Identification of continuous epitopes of HuD antibodies related to paraneoplastic diseases/small cell lung cancer. J Neuroimmunol 243:25–33CrossRefGoogle Scholar
  17. 17.
    Trier NH, Leth ML, Hansen PR, Houen G (2012) Cross-reactivity of a human IgG(1) anticitrullinated fibrinogen monoclonal antibody to a citrullinated profilaggrin peptide. Protein Sci 21:1929–1941CrossRefGoogle Scholar
  18. 18.
    Bizzaro N, Tonutti E, Tozzoli R, Villalta D (2007) Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 53:1527–1533CrossRefGoogle Scholar
  19. 19.
    Lutteri L, Malaise M, Chapelle JP (2007) Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clin Chim Acta 386:76–81CrossRefGoogle Scholar
  20. 20.
    Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808CrossRefGoogle Scholar
  21. 21.
    Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S, Bell M, Hudson M, Mathieu JP, Taillefer S, Jones N, Docherty P, Khraishi M, Markland J, Pope J, Robinson D, Smith D, Sutton E (2008) A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 27:77–83CrossRefGoogle Scholar
  22. 22.
    van Gaalen FA, Visser H, Huizinga TW (2005) A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis 64:1510–1512CrossRefGoogle Scholar
  23. 23.
    Pratesi F, Tommasi C, Anzilotti C, Puxeddu I, Sardano E, Di Colo G, Migliorini P (2011) Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies. Clin Exp Immunol 164:337–345CrossRefGoogle Scholar
  24. 24.
    Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386CrossRefGoogle Scholar
  25. 25.
    Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRefGoogle Scholar
  26. 26.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefGoogle Scholar
  27. 27.
    Sokka T, Abelson B, Pincus T (2008) Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 26:S35–S61PubMedGoogle Scholar
  28. 28.
    Humphreys JH, van Nies JA, Chipping J, Marshall T, van der Helm-van Mil AH, Symmons DP, Verstappen SM (2014) Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Res Ther 16:483CrossRefGoogle Scholar
  29. 29.
    Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, Fraser A, Emery P (2006) Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 45:478–480CrossRefGoogle Scholar
  30. 30.
    Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–1749CrossRefGoogle Scholar
  31. 31.
    van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50:709–715CrossRefGoogle Scholar
  32. 32.
    Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, Dijkmans BA, Hamann D (2005) Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 64:1199–1204CrossRefGoogle Scholar
  33. 33.
    van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7:R949–R958CrossRefGoogle Scholar
  34. 34.
    Anzilotti C, Riente L, Pratesi F, Chimenti D, Delle Sedie A, Bombardieri S, Migliorini P (2007) IgG, IgA, IgM antibodies to a viral citrullinated peptide in patients affected by rheumatoid arthritis, chronic arthritides and connective tissue disorders. Rheumatology (Oxford) 46:1579–1582CrossRefGoogle Scholar
  35. 35.
    Ioan-Facsinay A, Willemze A, Robinson DB, Peschken CA, Markland J, van der Woude D, Elias B, Menard HA, Newkirk M, Fritzler MJ, Toes RE, Huizinga TW, El-Gabalawy HS (2008) Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 58:3000–3008CrossRefGoogle Scholar
  36. 36.
    Suwannalai P, Willemze A, van Toorn L, Stoeken-Rijsbergen G, Levarht N, Drijfhout JW, Huizinga TW, Toes RE, Trouw LA (2011) The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA. Arthritis Res Ther 13:R195CrossRefGoogle Scholar
  37. 37.
    Nienhuis RL, Mandema E (1964) A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 23:302–305CrossRefGoogle Scholar
  38. 38.
    Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ (1979) Anti-keratin antibodies in rheumatoid arthritis. Br Med J 2:97–99CrossRefGoogle Scholar
  39. 39.
    Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, Serre G (1995) The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 95:2672–2679CrossRefGoogle Scholar
  40. 40.
    Simon M, Girbal E, Sebbag M, Gomes-Daudrix V, Vincent C, Salama G, Serre G (1993) The cytokeratin filament-aggregating protein filaggrin is the target of the so-called “antikeratin antibodies,” autoantibodies specific for rheumatoid arthritis. J Clin Invest 92:1387–1393CrossRefGoogle Scholar
  41. 41.
    Simon M, Vincent C, Haftek M, Girbal E, Sebbag M, Gomes-Daudrix V, Serre G (1995) The rheumatoid arthritis-associated autoantibodies to filaggrin label the fibrous matrix of the cornified cells but not the profilaggrin-containing keratohyalin granules in human epidermis. Clin Exp Immunol 100:90–98CrossRefGoogle Scholar
  42. 42.
    Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163CrossRefGoogle Scholar
  43. 43.
    Aggarwal R, Liao K, Nair R, Ringold S, Costenbader KH (2009) Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum 61:1472–1483CrossRefGoogle Scholar
  44. 44.
    Coenen D, Verschueren P, Westhovens R, Bossuyt X (2007) Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 53:498–504CrossRefGoogle Scholar
  45. 45.
    Correia ML, Carvalho S, Fortuna J, Pereira MH (2008) Comparison of three anti-CCP antibody tests and rheumatoid factor in RA and control patients. Clin Rev Allergy Immunol 34:21–25CrossRefGoogle Scholar
  46. 46.
    Fernandes-Cerqueira C, Ossipova E, Gunasekera S, Hansson M, Mathsson L, Catrina AI, Sommarin Y, Klareskog L, Lundberg K, Ronnelid J, Goransson U, Jakobsson PJ (2015) Targeting of anti-citrullinated protein/peptide antibodies in rheumatoid arthritis using peptides mimicking endogenously citrullinated fibrinogen antigens. Arthritis Res Ther 17:155CrossRefGoogle Scholar
  47. 47.
    Lundberg K, Bengtsson C, Kharlamova N, Reed E, Jiang X, Kallberg H, Pollak-Dorocic I, Israelsson L, Kessel C, Padyukov L, Holmdahl R, Alfredsson L, Klareskog L (2013) Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann Rheum Dis 72:652–658CrossRefGoogle Scholar
  48. 48.
    Wagner CA, Sokolove J, Lahey LJ, Bengtsson C, Saevarsdottir S, Alfredsson L, Delanoy M, Lindstrom TM, Walker RP, Bromberg R, Chandra PE, Binder SR, Klareskog L, Robinson WH (2015) Identification of anticitrullinated protein antibody reactivities in a subset of anti-CCP-negative rheumatoid arthritis: association with cigarette smoking and HLA-DRB1 ‘shared epitope’ alleles. Ann Rheum Dis 74:579–586CrossRefGoogle Scholar
  49. 49.
    Trier NH, Holm BE, Heiden J, Slot O, Locht H, Jensen B, Lindegaard H, Svendsen A, Nielsen CT, Jacobsen S, Theander E, Houen G (2018) The use of synthetic peptides for detection of anti-citrullinated protein antibodies in rheumatoid arthritis. J Immunol Methods 454:6–14CrossRefGoogle Scholar
  50. 50.
    Trier NH, Holm BE, Heiden J, Slot O, Locht H, Lindegaard H, Svendsen A, Nielsen CT, Jacobsen S, Theander E, Houen G (2018) Antibodies to a strain-specific citrullinated Epstein-Barr virus peptide diagnoses rheumatoid arthritis. Sci Rep 8:3684CrossRefGoogle Scholar
  51. 51.
    Holm BE, Bergmann AC, Hansen PR, Koch C, Houen G, Trier NH (2015) Antibodies with specificity for native and denatured forms of ovalbumin differ in reactivity between enzyme-linked immunosorbent assays. APMIS 123:136–145CrossRefGoogle Scholar
  52. 52.
    Svard A, Kastbom A, Reckner-Olsson A, Skogh T (2008) Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project. Arthritis Res Ther 10:R75CrossRefGoogle Scholar
  53. 53.
    Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ, Breedveld FC, Huizinga TW, Toes RE (2006) Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 54:3799–3808CrossRefGoogle Scholar
  54. 54.
    Soos L, Szekanecz Z, Szabo Z, Fekete A, Zeher M, Horvath IF, Danko K, Kapitany A, Vegvari A, Sipka S, Szegedi G, Lakos G (2007) Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 34:1658–1663PubMedGoogle Scholar
  55. 55.
    Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D, Gervasi G, Menard JF, Gayet A, Fardellone P, Daragon A, Jolivet M, le Loet X, Tron F (2004) Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 135:173–180CrossRefGoogle Scholar
  56. 56.
    Trier NH, Holm BE, Slot O, Locht H, Lindegaard H, Svendsen A, Houen G (2016) Physical characteristics of a citrullinated pro-filaggrin epitope recognized by anti-citrullinated protein antibodies in rheumatoid arthritis sera. PLoS One 11:e0168542CrossRefGoogle Scholar
  57. 57.
    Bartoloni E, Alunno A, Bistoni O, Bizzaro N, Migliorini P, Morozzi G, Doria A, Mathieu A, Lotzniker M, Allegri F, Riccieri V, Alpini C, Gabrielli A, Tampoia M, Gerli R, Autoimmuni i FI p l R n M (2012) Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev 11:815–820CrossRefGoogle Scholar
  58. 58.
    Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorini P (2006) Antibodies to viral citrullinated peptide in rheumatoid arthritis. J Rheumatol 33:647–651PubMedGoogle Scholar
  59. 59.
    Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P (2006) Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 54:733–741CrossRefGoogle Scholar
  60. 60.
    Szekanecz Z, Lakos G (2008) Rheumatoid arthritis diagnosis with antimutated citrullinated vimentin ELISA by Orgentec Diagnostika. Expert Opin Med Diagn 2:1083–1090CrossRefGoogle Scholar
  61. 61.
    Hussein MS, Ghany SEA, Elashkar DS, Rabea MY, Nosair NA (2016) Anti-CCP hs (high sensitive) in Egyptian rheumatoid arthritis patients associated with chronic hepatitis C virus infection. The Epyptian Rhumatolologist 38:15–20CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Autoimmunology and BiomarkersStatens Serum InstitutCopenhagen SDenmark

Personalised recommendations